The brain tumor board at Swedish/Cherry Hill successfully launched its first WebEx® conference on Monday, November 29 from a Seattle Science Foundation conference room. Dr. Namou Kim presented a case remotely from his office at First Hill, and an Ivy Center staff member attended the conference from the East Coast. The software allows providers to attend the conference remotely via desktop computer and telephone when a patient they refer is being discussed, or they can present films and pathology to the subspecialists present onsite at the conference. The program will now be rolled out to physicians throughout the Pacific Northwest. For more information or to present a case, contact John W. Henson, MD, FAAN, at email@example.com or 206-320-2300.
The Leapfrog Group’s annual class of top hospitals – 65 from a field of nearly 1,200 – was announced today in Washington, D.C. and, for the first time, included Swedish Medical Center’s First Hill and Cherry Hill campuses. The announcement came at Leapfrog’s 10th anniversary meeting. A complete list of 2010 Leapfrog Top Hospitals can be viewed at www.leapfroggroup.org.
The Leapfrog Group is a coalition of public and private purchasers of employee health coverage – including Boeing and the Washington State Healthcare Authority – which was founded a decade ago to work for improvements in health-care safety, quality and affordability. Initially organized by the Business Roundtable, it is now an independent advocacy group working with a broad range of partners, including hospitals and insurers.
The ‘Top Hospital’ selection is based on the results of the Leapfrog Group’s national survey, which launched in 2001. It measures hospitals’ performance in crucial areas of patient safety and quality, including:
- The use of computer physician order entry (CPOE) to prevent medication errors;
- Standards for doing high-risk procedures such as heart surgery;
- Protocols and policies to reduce medical errors and other safe practices recommended by the National Quality Forat um; and
- Adequate nurse and physician staffing
The results of the survey are posted www.leapfroggroup.org.
SNI Grand Rounds Series 2010 - MRI of Carotid Atherosclerosis and it's Role in Predicting Stroke/TIA
Presented By: Chun Yuan, Ph.D., Professor of Radiology, Adjunct Professor of Bioengineering, University of Washington Objectives: At the conclusion of this session, attendees will have an incresed ability to:
- Describe the need for plaque characterization in identifying high risk lesions
- Recall current MRI-based plaque imaging technique and it's ability for plaque characterization
SNI Grand Rounds Series is every 1st and 3rd Thursday of each month
Brian Louie, MD, FRCSC, FACS, Esophageal Surgery, Thoracic SurgeryObjectives:
At the conclusion of this session, attendees will have an increased ability to:
- Review the role of thymectomy in the management of myasthenia gravis and describe the options for thymectomy
- Discuss the management of thoracic neurogenic tumors and options for surgical treatment
- Discuss the role and outcomes of thoracic sympathectomy for hyperhidrosis
SNI Grand Rounds Series is every 1st and 3rd Thursday of each month.
The Multiple Sclerosis Center continues to grow. We have added an additional MS nurse, Reiko Aramaki, RN. Reiko joined us from the Evergreen MS Center. She is certified by the International Order of MS Nurses and will expand our ability to respond to patient’s needs.
Outreach programs also continue. Dr. Bowen was recently interviewed by Kathi Goertzen from KOMO TV4 regarding CCSVI. This interview can be seen at http://www.komonews.com/home/video/106166123.html.
Also, Chaz Gilbert, a patient care coordinator won the Seattle Verizon Urban Challenge on 10/30/10, racing through 12 checkpoints in their city using only clues, their feet and public transit.
The Pediatric Epilepsy and Pediatric Neurology services at Swedish Medical Center have combined to create the new Swedish Pediatric Neuroscience Center. As part of the Swedish Neuroscience Institute (SNI), comprehensive neurological care for newborns, infants, children and adolescents is now located at the Swedish First Hill campus in Seattle. Marcio Sotero de Menezes, M.D., has been appointed director of the new center.
The center has a high patient volume for the medical and surgical treatment of seizure disorders, including complex epilepsy syndromes and genetic epilepsies. It is accredited by the National Association of Epilepsy Centers as a Level-4 epilepsy center.
In addition to epilepsy, the center’s specialists treat pediatric patients for a wide range of neurological disorders, including headache and migraine; movement disorders, tics and Tourette’s syndrome; genetic and metabolic disorders; neurodevelopmental disorders and learning disabilities; brain malformations; cerebral palsy; stroke; tuberous sclerosis; and neurofibromatosis.
The center’s patients will also benefit from a broad spectrum of pediatric neurology inpatient hospital services, including epilepsy monitoring unit, pediatric and neonatal intensive care units, procedural sedation services, pediatric neurosurgery and intraoperative EEG monitoring, imaging services, and neuropsychological testing. Physical, occupational and speech therapy services are also available to the center’s patients.
For more information about the Swedish Pediatric Neuroscience Center, please call 206-215-1440.
ALEMTUZUMAB. 5-year data from a Phase II extension study for alemtuzumab, an intravenously administered monoclonal antibody, showed that the drug:
- reduced annualized rate of relapse to 0.14 compared with 0.28 for interferon
- reduced the risk for sustained accumulation of disability in remitting relapsing multiple sclerosis by 87% compared to 62% with interferon.
This is a remarkable agent with excellent activity in MS. Adverse events included immune thrombocytopenic purpura, thyroiditis and anti-glomerular basement membrane disease.
TERIFLUNOMIDE. A Phase III trial of oral teriflunomide in remitting relapsing MS showed:
- a 31% reduction in relapse rate and increased time to first relapse compared with placebo
- reduced the risk of sustained disability progression by 29.8%.
Side effects were mild and included diarrhea, nausea, liver function abnormalities and hair loss.
Alemtuzumab and teriflunomide are currently in Phase III clinical trials at SNI.
- Dr. Jim Bowen presented a poster about ongoing demyelination and neurodegeneration in a patient who had undergone autologous stem cell transplantation.
- Drs. Jung Henson and Mayadev reviewed the beneficial effects of exercise on functional and quality of life outcomes from SNI’s MS wellness program